Blog
RSS FeedPosted by Michael Wonder on 02 Mar 2016
UK cost agency rejects leukaemia drug from J&J and AbbVie
1 March 2016 - A new leukaemia drug viewed by industry experts as a future blockbuster has been rejected by Britain's ...
Posted by Michael Wonder on 25 Feb 2016
Praxbind (idarucizumab) reimbursed in England, Ireland and Wales
17 February 2016 - Praxbind (idarucizumab) is now available to be used commercially in England, Ireland and Wales after the Health ...
Posted by Michael Wonder on 24 Feb 2016
NICE final nod for MSD's cholesterol buster Ezetrol
24 February 2016 - In final guidelines, the National Institute for Health and Care Excellence says the drug can be used ...
Posted by Michael Wonder on 23 Feb 2016
Final NICE nod for Opdivo in skin cancer
22 February 2016 - Patients with advanced forms of skin cancer should have the option of treatment with Bristol-Myers Squibb’s immunotherapy ...
Posted by Michael Wonder on 19 Feb 2016
NICE calls for more research into promising new drug to treat inherited rare enzyme deficiency
18 February 2016 - The draft guidance recommends that the research should be designed to generate robust evidence about the costs ...
Posted by Michael Wonder on 18 Feb 2016
UK cost agency queries value of $700,000-a-year Alexion drug
18 February 2016 - An enzyme treatment from Alexion Pharmaceuticals costing 491,992 pounds ($704,630) a year may be worth using in ...
Posted by Michael Wonder on 08 Feb 2016
NICE issues draft guidance on alirocumab for lipid disorder
8 February 2016 - NICE has published draft guidance not recommending alirocumab (Praluent, Sanofi/Regeneron) as an option for people with high ...
Posted by Michael Wonder on 27 Jan 2016
NICE publishes final drug recommendations for 5 separate medical conditions
27 January 2016 - Each piece of guidance looked at the cost-effectiveness of a particular drug to treat a specific medical ...
Posted by Michael Wonder on 26 Jan 2016
NICE issues final guidance recommending 7 drugs for rheumatoid arthritis
26 January 2016 - In final updated guidance published today NICE recommends a number of drugs called biological disease modifying drugs ...
Posted by Michael Wonder on 23 Jan 2016
NICE draft guidance recommends nivolumab for advanced skin cancer
22 January 2016 - The independent Committee decided that a consultation on the draft recommendations was not needed for this appraisal, ...
Posted by Michael Wonder on 04 Jan 2016
NICE public board meeting and NICE question time – Salisbury
4 January 2016 - Every two months the NICE Board holds its meeting in a different venue; moving from region to ...
Posted by Michael Wonder on 28 Dec 2015
NICE issues revised draft guidance on ezetimibe for hypercholesterolaemia
24 December 2015 - NICE is reviewing its guidance on ezetimibe (Ezetrol, MSD) for adults with primary (heterozygous-familial and non-familial) hypercholesterolaemia. ...
Posted by Michael Wonder on 16 Dec 2015
NICE recommends elosulfase alfa (Vimizim) for treatment of very rare life-limiting genetic disorder under managed access agreement
16 December 2015 - In final guidance as part of its Highly Specialised Technologies Programme, NICE has recommended Elosulfase alfa (Vimizin, ...
Posted by Michael Wonder on 16 Dec 2015
NICE issues guidance not recommending apremilast for psoriatic arthritis
16 December 2015 - NICE has published final guidance today which does not recommend apremilast (Otezla, Celgene) for adults with active ...
Posted by Michael Wonder on 16 Dec 2015
Kadcyla price too high for routine NHS funding, says NICE in final guidance
16 December 2015 - NICE has issued its final guidance on the use of Kadcyla (trastuzumab emtansine) as a treatment for ...